Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Markets to 2023: Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market - Research and Markets
DUBLIN, Apr. 07, 2017 /PRNewswire/ --
Research and Markets has announced the addition of the "Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market" report to their offering.
The NSCLC market in Asia-Pacific is forecast to grow substantially, from $3 billion in 2016 to $6.2 billion in 2023, at a compound annual growth rate (CAGR) of 10.8%.
Owing to strong clinical performances, immune-checkpoint inhibitors will have a greater uptake than other second-line market entrants and will compete among themselves for market share in the APAC region. The entry of targeted therapies into the market will offset the effect of patent expiries for drugs such as Avastin, Alimta, and Tarceva, which will have a limited impact on the market between 2016 and 2023.
New targeted and immuno-therapies will drive market growth due to premium pricing and strong clinical performances, but they will also increase the degree of NSCLC market segmentation and the complexity of the treatment algorithm, owing to their enhanced efficacy in specific patient populations. The limited effect of patent expiry on the NSCLC market is one of the main reasons for the substantial growth in value expected in the forecast period, as the introduction of numerous therapies will not be offset by generic erosion; instead, premium therapies will occupy a larger market share for much of the forecast period in APAC.
The rate of mutation testing is very low in China and India compared with Australia, South Korea and Japan, and this makes many patients ineligible to receive targeted therapies. However, it is increasing, driven by increasing awareness among the healthcare fraternity. Hence, targeted therapies are expected to be used more often, driving market growth. Moreover, healthcare access and awareness have improved in India and China due to government initiatives. This will increase the market size by strengthening the treatment pool.
Key Topics Covered:
1 Introduction
1.1 Disease Introduction
1.2 Epidemiology
1.3 Symptoms
1.4 Etiology and Pathophysiology
1.5 Diagnosis
1.6 Prognosis
1.7 Treatment Guidelines and Options
2 Marketed Products
2.1 Overview
2.2 Chemotherapies
2.2.1 Alimta (pemetrexed) - Eli Lilly
2.2.2 Abraxane (paclitaxel) - Celgene
2.3 Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
2.3.1 Tarceva (erlotinib) - Roche
2.3.2 Iressa (gefitinib) - AstraZeneca
2.3.3 Gilotrif/Giotrif/Xovoltib (afatinib) - Boehringer Ingelheim
2.3.4 Tagrisso (osimertinib/AZD-9291) - AstraZeneca
2.3.5 Olita (olmutinib) - Hanmi Pharmaceuticals
2.3.6 Conmana (icotinib) - Betta Pharmaceuticals
2.4 Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors
2.4.1 Xalkori (crizotinib) - Pfizer
2.4.2 Alecensa (alectinib) - Roche
2.4.3 Zykadia (ceritinib/LDK378) - Novartis
2.5 Programmed Cell Death Protein 1/Programmed Death Ligand 1 Immune Checkpoint Inhibitors
2.5.1 Opdivo (nivolumab) - Bristol-Myers Squibb
2.5.2 Keytruda (pembrolizumab) - Merck & Co
2.6 Other
2.6.1 Avastin (bevacizumab) - Roche
2.6.2 Cyramza (Ramucirumab) - Eli Lilly
2.6.3 Ofev/Vargatef (Nintedanib) - Boehringer Ingelheim
2.7 Conclusion
2.8 Comparative Efficacy and Safety of Marketed Products
3 Pipeline Analysis
3.1 Overview
3.2 Pipeline by Stage of Development, Molecule Type, Route of Administration and Program Type
3.3 Pipeline by Molecular Target
3.4 Promising Pipeline Candidates
3.4.1 Yervoy (Ipilimumab) - Bristol-Myers Squibb
3.4.2 Tecentriq (Atezolizumab) - Roche
3.4.3 Necitumumab - Eli Lilly
3.4.4 Durvalumab plus Tremelimumab (MEDI-4736/MEDI-1123) - MedImmune
3.4.5 Veliparib - AbbVie
3.4.6 Vaxira - Recombio
3.4.7 Abemaciclib - Eli Lilly
3.4.8 Dacomitinib - Pfizer
3.4.9 Ensartinib (X-396) - Xcovery
3.4.10 Anlotinib (AL-3818) - Jiangsu Chia-Tai Tianqing
3.4.11 CimaVax-EGF (BVNSCLC-001) - Bioven
3.4.12 Brigatinib (AP-26113) - Ariad Pharmaceuticals
3.4.13 Naquotinib Mesylate (ASP8273) - Astellas Pharma
3.4.14 Plinabulin - BeyondSpring Pharma
3.4.15 Fruquintinib (HMPL-013) - Hutchison MediPharma
3.4.16 Famitinib (SHR-1020) - Jiangsu Hengrui Medicine
3.4.17 Vandetanib (ZD 6474) - Genzyme
3.4.18 Aitan (Apatinib) - Jiangsu Hengrui Medicine
3.5 Comparative Efficacy and Safety of Pipeline Products
3.6 Product Competitiveness Framework
4 Clinical Trial Analysis
4.1 Failure Rate
4.1.1 Overall Failure Rate
4.1.2 Failure Rate by Phase and Molecule Type
4.1.3 Failure Rate by Phase and Molecular Target
4.2 Clinical Trial Size
4.2.1 Patient Enrollment per Product by Molecule Type and Stage of Development
4.2.2 Patient Enrollment per Product by Molecular Target and Stage of Development
4.2.3 Patient Enrollment per Trial by Molecule Type and Stage of Development
4.2.4 Patient Enrollment per Trial by Molecular Target and Stage of Development
4.3 Clinical Trial Duration
4.3.1 Trial Duration by Molecule Type and Stage of Development
4.3.2 Trial Duration by Molecular Target and Stage of Development
4.4 Summary of Clinical Trial Metrics
5 Multi-scenario Forecast
- Treatment Usage Patterns
- Annual Cost of Therapy
- Market Size
6 Drivers and Barriers
6.1 Drivers
6.1.1 Increasing Pollution and Passive Smoking to Drive the Incidence
6.1.2 Increasing Elderly Population and Incidence of NSCLC
6.1.3 The Availability of Novel First- and Second-Line Therapy Options in Pipeline
6.1.4 Increase in Mutation Testing to Drive Market Growth
6.1.5 Diversified Healthcare Reform to Boost Market Growth
6.1.6 Diversified Health Insurance System to Help Nurture Growth
6.2 Barriers
6.2.1 Patent Expiration of Branded Therapies to Affect NSCLC Market Growth
6.2.2 High Prices of Therapeutics to Slow Down Market Growth
6.2.3 Lack of Reimbursement and Penetration of Generic Drugs to Hinder Market Growth in China and India
6.2.4 Drug Pricing Reforms
7 Deals and Strategic Consolidations
7.1 Licensing Deals
7.1.1 Deals by Region and Value
7.1.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.1.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
7.1.4 Key Licensing Deals
7.2 Co-development Deals
7.2.1 Deals by Region and Value
7.2.2 Number of Disclosed and Undisclosed Deals by Year, Aggregate Deal Value
7.2.3 Deal Value by Stage of Development, Molecule Type, and Molecular Target
7.2.4 Key Co-development Deals
8 Appendix
8.1 All Pipeline Drugs by Stage of Development
8.1.1 Discovery
8.1.2 Preclinical
8.1.3 Investigational New Drug/Clinical Trial Authorization-Filed
8.1.4 Phase I
8.1.5 Phase II
8.1.6 Phase III
8.1.7 Pre-registration
8.2 Summary of Multi-scenario Market Forecasts to 2023
8.2.1 Asia-Pacific
8.2.2 India
8.2.3 China
8.2.4 Australia
8.2.5 South Korea
8.2.6 Japan
8.3 Bibliography
8.4 Abbreviations
For more information about this report visit http://www.researchandmarkets.com/research/wmv5j4/nonsmall_cell
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
Share this article